Imagenebio (IMA) closed at $3.98 on November 19, 2026, up 4.5% from the previous close, on volume of 27,539 shares (30-day average 15,382).
Data as of November 19, 2026.
ImageneBio Reports Third Quarter 2026 Financial Results
Globe Newswire (Mon, 9-Nov 4:05 PM ET)
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 2-Oct 4:30 PM ET)
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
Globe Newswire (Tue, 8-Sep 4:30 PM ET)
ImageneBio Secures $30 Million Private Placement to Accelerate Development of Lead Program IMG-007
Market Chameleon (Mon, 13-Apr 6:46 AM ET)
ImageneBio Secures $30 Million in Private Funding to Advance Promising OX40 Antagonist IMG-007
Market Chameleon (Mon, 13-Apr 4:25 AM ET)
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
Imagenebio trades on the NASDAQ stock market under the symbol IMA.
As of November 19, 2026, IMA stock price climbed to $3.98 with 27,539 million shares trading.
IMA has a market cap of $45.18 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that IMA belongs to (by Net Assets): VTI, VXF, IWC.
IMA has underperformed the market in the last year with a return of -47.8%, while the SPY ETF gained +9.6%. In the last 3 month period, IMA fell short of the market, returning -29.9%, while SPY returned -6.5%. However, in the most recent 2 weeks IMA has outperformed the stock market by returning -2.9%, while SPY returned -6.6%.
IMA support price is $3.55 and resistance is $4.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMA shares will trade within this expected range on the day.